Abstract |
Pancreatic cancer immunotherapy is becoming a promising strategy for improving the survival rate of postsurgical patients. However, the low response rate to immunotherapy suggests a low number of antigen-specific T cells and a high number of immunosuppressive tumor-associated macrophages in the pancreatic tumor microenvironment. Herein, we developed an in situ injectable thermosensitive chitosan hydrogel loaded with lipid-immune regulatory factor 5 (IRF5) mRNA/ C-C chemokine ligand 5 (CCL5) siRNA (LPR) nanoparticle complexes (LPR@CHG) that reprogram the antitumoral immune niche. The LPR@CHG hydrogel upregulates IRF5 and downregulates CCL5 secretion, which contribute to a significant increase in M1 phenotype macrophages. Tumor growth is controlled by effective M1 phenotype macrophage that initiate T cell-mediated immune responses. Overall, the LPR@CHG hydrogel is expected to be a meaningful immunotherapy platform that can reshape the immunosuppressive tumor microenvironment and improve the efficacy of current pancreatic immunotherapies while minimizing systemic toxicity.
|
Authors | Chao Gao, Keman Cheng, Yao Li, Ruining Gong, Xiao Zhao, Guangjun Nie, He Ren |
Journal | Nano letters
(Nano Lett)
Vol. 22
Issue 22
Pg. 8801-8809
(11 23 2022)
ISSN: 1530-6992 [Electronic] United States |
PMID | 36251255
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Lipid Nanoparticles
- Hydrogels
- RNA, Small Interfering
- Immunologic Factors
- Interferon Regulatory Factors
|
Topics |
- Humans
- Tumor Microenvironment
- Hydrogels
- Nanoparticles
- Immunotherapy
- RNA, Small Interfering
(genetics, therapeutic use)
- Pancreatic Neoplasms
(drug therapy)
- Immunologic Factors
- Interferon Regulatory Factors
- Pancreatic Neoplasms
|